PLX Breakout Trade Setup: Entry, Targets & Risk Friday!Stop-Loss (SL): 2.14 📉
Entry: Above 2.27 📈
Target 1 (T1): 2.40 🎯
Target 2 (T2): 2.58 🚀
Conclusion:
A break above 2.27 suggests bullish momentum. Targets are 2.40 and 2.58, with 2.14 as SL to mitigate risk.
💡 Follow your plan!
⚠️ Risk-Reward is favorable.
📈 PLX Breakout opportunity!
PLX trade ideas
mid term +15,000%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease.
$PLX - "Buy on rumor sell on news"?, Yet, BLA and BRIGHT aheadProtalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended to buy or sell PLX stocks.
$PLX - The most important year for PROTALIX Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
Tomorrow may tell..As most of us know this stock doesn't deal well with resistance !! So..after poking through support I really have no idea what will happen tomorrow. I am invested in this and like many cant seem to understand why this stock has such weak abilities. Hopefully... it draws some buyers here soon and can rise above support. But it may just keep dipping lower till closer to Jan 26th. I believe thats the date. Anyone who has held this for yrs... myself included. Lets try and gather our strength and hold out for at least 8.49!! Sigh
$PLX - Turtle progress (Today's announcement - read below)CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE
American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development,
production and commercialization of recombinant therapeutic proteins produced by its
proprietary ProCellEx® plant cell-based protein expression system, today announced completion
of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or
PRX-102, for the proposed treatment of Fabry disease. The Company is currently working with
its service providers to complete the final monitoring visits necessary for final analysis of the
data; however, many sites are still impacted by ongoing local and state restrictions and
precautions due to the COVID-19 pandemic. The Company anticipates announcing top-line
results in the fourth quarter of 2020 once this process is completed.
“Completion of the BRIGHT study marks another important key milestone in our pursuit of an
alternative dose and regimen of pegunigalsidase alfa for the proposed treatment of Fabry
disease,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics.
“We eagerly anticipate announcement of top-line data, and are working towards the completion
of the final monitoring visits as quickly as possible. Our challenge now is to continue the work to
finalize these last details with the ongoing headwinds from COVID-19. I am very proud of our
team’s execution in completing the study and am confident in their ability to have the final data
as expeditiously as possible.”
Mr. Bashan continued, “The BRIGHT study is the second Phase III study of PRX-102 in Fabry
patients that we have completed as part of our comprehensive PRX-102 development program.
We announced positive results earlier this year from our Phase III BRIDGE clinical trial, and we
anticipate results from an interim analysis of our Phase III BALANCE clinical trial in the first
half of 2021. In addition, earlier this month, we announced the filing of the PRX-102 BLA by the
U.S. Food and Drug Administration with a PDUFA target date of January 27, 2021.”
Very Risky stock
Not for any advise